Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/13/2008 First Published: 1/23/2004


1.		Phase II Study of Induction Chemotherapy Comprising Doxorubicin and Cisplatin Followed By Combretastatin A4 Phosphate and Radiotherapy in Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer (Phase I portion of the study closed as of 5/6/04)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				CASE-CWRU-3302 CWRU-040337, OXIGENE-CWRU-3302, NCT00077103, CASE-3302

Last Modified: 12/31/2008 First Published: 4/23/2003


2.		Phase II Study of Combretastatin A4 Phosphate in Patients With Advanced Anaplastic Thyroid Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CASE-CWRU-ICC-2302 NCT00060242, CASE-2302


3.		Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA4P-212 HCI-13214, NCT00113438

Last Modified: 2/26/2008 First Published: 2/1/1999


4.		Phase I Study of Combretastatin A4 Phosphate in Patients with Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over								CRC-PHASE-I/II-PH1/066 EU-98066, NCT00003698

Last Modified: 5/1/2001 First Published: 3/1/1999


5.		Phase I Study of Combretastatin A4 Phosphate in Patients With Advanced Solid Tumors (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-ILEX-1Y98 ILEX-1Y98, ILEX-CA4P101-A3, NCI-G99-1502, NCT00003768


6.		Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				OXC4P1-105 NCT00395434

Select All on One Page